Joshi Neeraj, Mariam Haifa, Kamath Ashwin
Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
Med Cannabis Cannabinoids. 2024 Sep 16;7(1):183-192. doi: 10.1159/000541461. eCollection 2024 Jan-Dec.
Glaucoma is an ocular disease with significant health burden. Despite the availability of many antiglaucoma drugs, a significant proportion of patients may experience worsening of the disease. Hence, there is a need for newer antiglaucoma drugs.
Natural and synthetic derivatives of cannabis plants have been studied in the treatment of glaucoma since the 1970s. This review describes the potential mechanisms of the cannabinoids in the treatment of glaucoma, summarizes the findings of clinical studies describing the efficacy of these compounds, and describes the adverse effects observed with the various cannabinoid formulations evaluated in clinical studies of glaucoma in healthy volunteers and patients. The implications of these findings in terms of the potential clinical status of cannabinoids in the treatment of glaucoma and the challenges involved have also been described.
Cannabinoids lower intraocular pressure. However, the effect is short-lived. There is also a lack of well-formulated ocular delivery system. The available evidence is inadequate to recommend the use of cannabinoids for the routine treatment of glaucoma.
青光眼是一种具有重大健康负担的眼部疾病。尽管有许多抗青光眼药物可供使用，但仍有相当一部分患者的病情可能会恶化。因此，需要更新的抗青光眼药物。
自20世纪70年代以来，大麻植物的天然和合成衍生物已被研究用于治疗青光眼。本综述描述了大麻素治疗青光眼的潜在机制，总结了描述这些化合物疗效的临床研究结果，并描述了在健康志愿者和患者青光眼临床研究中评估的各种大麻素制剂所观察到的不良反应。还描述了这些发现在大麻素治疗青光眼的潜在临床地位方面的意义以及所涉及的挑战。
大麻素可降低眼压。然而，这种效果是短暂的。此外，缺乏完善的眼部给药系统。现有证据不足以推荐将大麻素用于青光眼的常规治疗。
